Chembond Material Technologies Limited (formerly Chembond Chemicals Limited) has approved its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a Board of Directors meeting held on May 15, 2026. The results were reviewed by the Audit Committee and audited by M/s. Kastury & Talati, Chartered Accountants, who issued unmodified audit opinions on both standalone and consolidated financial statements. In addition to approving the results, the Board recommended a dividend of ₹2.00 per equity share of face value ₹5 each (40%), subject to shareholder approval at the ensuing 51st Annual General Meeting. The submission was made pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Consolidated Financial Performance

On a consolidated basis, Chembond Material Technologies reported revenue from operations of ₹25,007.40 lakhs for the year ended March 31, 2026, compared to ₹20,129.99 lakhs in the previous year. Total income for the year stood at ₹25,274.34 lakhs. The company recorded a net profit of ₹1,289.07 lakhs for the year, while total comprehensive income stood at ₹1,311.78 lakhs. The key consolidated financial metrics are presented below:

The exceptional item for the year reflects the incremental effect on gratuity of ₹(132.48) lakhs, arising from the notification of new Labour Codes effective from November 21, 2025, accounted for based on actuarial valuation.

Standalone Financial Performance

On a standalone basis, Chembond Material Technologies reported revenue from operations of ₹21,014.12 lakhs for the year ended March 31, 2026, compared to ₹17,120.70 lakhs in the previous year. Profit before tax for the year stood at ₹1,021.01 lakhs, while net profit for the year was ₹775.88 lakhs. The standalone financial highlights are as follows:

Segment-wise Performance

The Group operates across two reportable business segments: Specialty Chemicals and Animal Health. The consolidated segment-wise revenue and results for the year ended March 31, 2026 are presented below:

Segment assets as at March 31, 2026 stood at ₹20,220.92 lakhs for Specialty Chemicals and ₹1,721.11 lakhs for Animal Health, aggregating to total assets of ₹21,942.02 lakhs. Segment liabilities totalled ₹5,247.91 lakhs.

Consolidated Balance Sheet Highlights

The consolidated statement of assets and liabilities as at March 31, 2026 reflects total assets of ₹21,942.02 lakhs, compared to ₹20,173.96 lakhs as at March 31, 2025. Total equity stood at ₹16,694.12 lakhs, comprising equity share capital of ₹672.41 lakhs and other equity of ₹16,021.70 lakhs.

Cash and cash equivalents as at March 31, 2026 stood at ₹940.78 lakhs on a consolidated basis, up from ₹600.72 lakhs as at March 31, 2025. Net cash from operating activities for the year was ₹1,479.15 lakhs, while net cash used in investing activities was ₹(1,018.13) lakhs.

ESOP and Other Disclosures

The company granted stock options to eligible employees under the Chembond – ESOP 2025 scheme. In accordance with Ind AS 102 – Share-based Payment, an employee compensation expense of ₹1.13 lakhs has been recognised under Employee Benefits Expense for the quarter and year ended March 31, 2026. The Group has also decided to continue with the existing tax structure as prescribed under the Income Tax Act, 1961. The detailed financial results are available on the BSE ( www.bseindia.com ), NSE ( www.nseindia.com ), and the company's website at www.chembond.in . The filing was signed by Suchita Singh, Company Secretary & Compliance Officer, and Rashmi Gavli, Chief Financial Officer, on May 15, 2026.

Chembond Material Technologies Limited (formerly Chembond Chemicals Limited) has informed the stock exchanges of a forthcoming board meeting, scheduled for Friday, May 15, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 7, 2026, and signed by Company Secretary & Compliance Officer Suchita Singh and Chief Financial Officer Rashmi Gavli.

Agenda of the Board Meeting

The board meeting has been convened to address key financial and corporate matters for the concluded fiscal year. The following items are on the agenda:

• Consideration and approval of audited financial results on both standalone and consolidated basis for the quarter and year ended March 31, 2026.
• Recommendation of dividend for FY 2025-26, subject to board discretion.

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct for prevention of insider trading, the trading window for Directors, Officers, and Designated Persons of the company will remain closed until 48 hours after the outcome of the board meeting. The key dates pertaining to the trading window are as follows:

The trading window closure was originally communicated via the company's letter reference SE/CS/2025-26/85 dated March 24, 2026. Chembond Material Technologies has directed the exchanges to take the above information on record.